Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia

Gianantonio Rosti • 12 Jun 2015
EHA 2015
Chronic Myeloid Leukemia

Advances in the biological understanding of chronic myeloid leukemia (CML) and therapy with tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for patients with CML. At the 20th Congress of the European Hematology Association (EHA), Gianantonio Rosti, MD, of the University of Bologna, Bologna, Italy, considers the feasibility of first- and second-generation TKI treatment discontinuation in patients with CML, as well as how monitoring treatment responses and patient advocacy can impact outcomes.

More from Gianantonio Rosti

3:15
New horizons in CML
Gianantonio Rosti • 13 Jun 2019
2:17
Current CML treatments: which TKI to choose?
Gianantonio Rosti • 13 Jun 2019
1:55
Long-term monitoring, adherence & endpoints in CML
Gianantonio Rosti • 13 Jun 2019

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
3:21
A Phase I trial of Hu8F4, an anti-PR1/HLA-A2 monoclonal antibody, in R/R myeloid malignancies
Tapan Kadia • 14 Dec 2023
6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
The content of VJHemOnc is intended for healthcare professionals